Physician profile
Amar Dixit
NPI 1316381650
$345,413.73
in general payments reported to CMS, 2019-2025
31 companies · $165K in 2025
The $165K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,504 · 2020: $472 · 2021: $12K · 2022: $37K · 2023: $40K · 2024: $89K · 2025: $165K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $160K · Consulting Fee: $74K · Travel and Lodging: $47K · Food and Beverage: $14K · Education: $23.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $159,661.56 |
| Consulting Fee | $74,168.38 |
| Travel and Lodging | $46,737.66 |
| Food and Beverage | $13,686.95 |
| Education | $23.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125,401.75 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $48,162.68 | 2021-2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $41,783.20 | 2023-2025 | |
| Ars Pharmaceuticals Operations, INC. | $30,736.95 | 2025 | Neffy |
| Csl Behring | $28,810.14 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $25,338.27 | 2020-2025 | Cinryze, Eohilia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $23,607.65 | 2019-2025 | Dupixent |
| Incyte Corporation | $13,155.54 | 2025 | Opzelura |
| Astrazeneca Pharmaceuticals Lp | $2,142.05 | 2020-2025 | Tezspire |
| Dermavant Sciences, INC. | $2,008.81 | 2024 | Vtama |
| Allerderm Laboratories | $1,000.00 | 2019 | |
| Glaxosmithkline, LLC. | $777.24 | 2019-2025 | Nucala |
| Pharming Healthcare, INC. | $553.88 | 2020-2022 | |
| Octapharma USA, INC. | $501.92 | 2021-2025 | Cutaquig |
| Alk-Abello, INC | $236.10 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198.95 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $182.75 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.91 | 2022 | |
| Aquestive Therapeutics, INC. | $152.93 | 2025 | |
| Optinose US, INC. | $80.41 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $74.23 | 2024 | Dupixent |
| Ionis Pharmaceuticals, INC. | $64.77 | 2025 | Dawnzera |
| Amgen INC. | $62.46 | 2022-2023 | Tezspire |
| Genentech USA, INC. | $45.50 | 2021-2022 | |
| Biocryst Pharmaceuticals, INC. | $42.09 | 2020 | |
| Blueprint Medicines Corporation | $27.01 | 2022 | |
| Leo Pharma INC. | $21.73 | 2022 | |
| Adma Biomanufacturing LLC | $21.42 | 2021 | |
| Horizon Therapeutics Plc | $18.09 | 2020 | |
| Uswm, LLC | $17.47 | 2021 | |
| Grifols USA, LLC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Dixit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.